In addition, a number of studies have demonstrated that cancer immunotherapy strategies that block the interaction between PD‐1 and PD‐L1 can restore T‐cell activity and lead to tumour regression in both humans and animals.17, 21, 22, 23. The gene discussed is CD274; the disease is cancer.